Pfizer has earned a consensus rating of “Moderate Buy” from fifteen analysts, with only one calling it a “sell.” The average ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

This article conducts technical analysis and provides forecasts for top trending stocks like Plug Power (PLUG), Uber, and ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Sector-by-sector analysis throws a spotlight on high-yielding winners in more defensive areas of the stock market.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, respectively, with AstraZeneca coming in a respectable third with 14 per cent.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

My final reason for buying more Pfizer stock is that I'll get paid nicely to wait and see if the drugmaker lives up to Wall Street's growth outlook. Pfizer's forward dividend yield currently stands at ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

InvestingPro analysis reveals 10+ additional exclusive tips about Pfizer’s financial health and market position. Key Takeaways Pfizer’s Q1 2025 EPS of $0.92 exceeded forecasts by 35%.

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock ...